Kirkeby H J, Petersen T, Poulsen E U
Department of Urology, Aarhus Kommunehospital, Denmark.
Scand J Urol Nephrol. 1988;22(4):241-4. doi: 10.3109/00365598809180793.
Intracavernous injection of papaverine was tested in a group of 29 patients with multiple sclerosis and erectile dysfunction. Acceptable rigidity was obtained in 27 patients of whom 23 started to use self-injections as treatment. During an observation period of 5-12 months (mean 8.5 months) a total of 297 injections (3-35 per patient) were reported and 272 injections (92%) produced rigidity in 8-480 min. One case of priapism was seen. Minor haematomas or ecchymoses were reported in 16 cases. Two patients developed penile indurations after 6 and 19 injections respectively; one of these indurations resolved spontaneously. Self-injection with papaverine was found to be a safe and well-accepted treatment of erectile dysfunction in multiple sclerosis but long term side effects need further elucidation before the treatment is to be used as a routine procedure.
对一组29例患有多发性硬化症和勃起功能障碍的患者进行了海绵体内注射罂粟碱的测试。27例患者获得了可接受的硬度，其中23例开始使用自我注射作为治疗方法。在5至12个月（平均8.5个月）的观察期内，共报告了297次注射（每位患者3至35次），272次注射（92%）在8至480分钟内产生了硬度。观察到1例阴茎异常勃起病例。16例报告有轻微血肿或瘀斑。两名患者分别在注射6次和19次后出现阴茎硬结；其中1例硬结自行消退。发现罂粟碱自我注射是治疗多发性硬化症勃起功能障碍的一种安全且被广泛接受的方法，但在将该治疗用作常规程序之前，长期副作用需要进一步阐明。
